Health TrialsbyHealthPanel

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

Participants needed: 110
Trial details
Phase: Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: Janux TherapeuticsUpdated: Sep 17, 2026Locations: 1
Eligibility criteria

Male participants ≥ 18 years of age at the time of signing informed consent [+3]

Prior treatment with any chimeric antigen receptor (CAR) T-cell therapy, any app... [+2]

Read more
Status: Recruiting

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).

Participants needed: 43
Trial details
Phase: Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: Janux TherapeuticsUpdated: Sep 3, 2026Locations: 6
Eligibility criteria

Male ≥18 years of age at the time of signing informed consent [+4]

Prior solid organ transplant [+2]

Read more
Status: Recruiting

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

Participants needed: 272
Trial details
Phase: Phase 1Age: 18-100Biological sex: MaleType: InterventionalSponsor: Janux TherapeuticsUpdated: Aug 13, 2026Locations: 36
Eligibility criteria

Male ≥18 years of age at the time of signing informed consent [+7]

Prior solid organ transplant [+8]

Read more
Status: Recruiting

Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.

This first-in-human (FIH) study aims to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JANX011 dosed subcutaneously (and potentially intravenously) in healthy adult volunteers (HVs) to gain insight into its therapeutic utility in patients with autoimmune diseases.

Participants needed: 60
Trial details
Phase: Early Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Janux TherapeuticsUpdated: Apr 23, 2026Locations: 1
Eligibility criteria

Healthy men and women, in the opinion of the PI or designee and as determined by... [+2]

Recent surgery requiring general anesthesia within 12 weeks prior to Screening o... [+3]

Read more